» Articles » PMID: 24348300

Spasticity - Pathogenesis, Prevention and Treatment Strategies

Overview
Journal Saudi J Anaesth
Specialty Anesthesiology
Date 2013 Dec 19
PMID 24348300
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

This review of the long-term management of spasticity addresses some of the clinical dilemmas in the management of patients with chronic disability. It is important for clinicians to have clear objectives in patient treatment and the available treatment strategies. The review reiterates the role of physical treatment in the management, and thereafter the maintenance of patients with spasticity. Spasticity is a physiological consequence of an injury to the nervous system. It is a complex problem which can cause profound disability, alone or in combination with the other features of an upper motor neuron syndrome, and can give rise to significant difficulties in the process of rehabilitation. This can be associated with profound restriction to activity and participation due to pain, weakness, and contractures. Optimum management is dependent on an understanding of its underlying physiology, an awareness of its natural history, an appreciation of the impact on the patient, and a comprehensive approach to minimizing that impact. The aim of this article is to highlight the importance, basic approach, and management options available to the general practitioner in such a complex condition.

Citing Articles

Multimodal therapy and use of adjunctive therapies to BoNT-A in spasticity management: defining terminology to help enhance spasticity treatment.

Reebye R, Jacinto L, Balbert A, Biering-Sorensen B, Carda S, Draulans N Front Neurol. 2024; 15:1432330.

PMID: 39281409 PMC: 11392737. DOI: 10.3389/fneur.2024.1432330.


Localizing motor entry points of adductor muscles of thigh for motor point procedures in the treatment of adductor spasticity.

Albert A, Magimairaj H, Lakshmanan J, Holla S, Prithishkumar I Anat Cell Biol. 2024; 57(4):503-510.

PMID: 39192824 PMC: 11663516. DOI: 10.5115/acb.24.065.


Increased astrocytic GLT-1 expression in tripartite synapses is associated with SCI-induced hyperreflexia.

Benson C, King J, Kauer S, Waxman S, Tan A J Neurophysiol. 2023; 130(5):1358-1366.

PMID: 37877184 PMC: 10972632. DOI: 10.1152/jn.00234.2023.


A Cost-Effectiveness and Budget Impact Analysis of AbobotulinumtoxinA in Greece.

Nomikos N, Eleftheriou C, Athanasakis K Toxins (Basel). 2023; 15(9).

PMID: 37755987 PMC: 10534563. DOI: 10.3390/toxins15090561.


Effect of transcutaneous spinal direct current stimulation on spasticity in upper motor neuron conditions: a systematic review and meta-analysis.

Hassan A, Salihu A, Masta M, Gunn H, Marsden J, Abdullahi A Spinal Cord. 2023; 61(11):587-599.

PMID: 37640926 DOI: 10.1038/s41393-023-00928-9.


References
1.
KHALILI A, HARMEL M, Forster S, Benton J . MANAGEMENT OF SPASTICITY BY SELECTIVE PERIPHERAL NERVE BLOCK WITH DILUTE PHENOL SOLUTIONS IN CLINICAL REHABILITATION. Arch Phys Med Rehabil. 1964; 45:513-9. View

2.
Price R, LEHMANN J, Burleigh A, deLateur B . Influence of cryotherapy on spasticity at the human ankle. Arch Phys Med Rehabil. 1993; 74(3):300-4. View

3.
Bohannon R, Smith M . Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987; 67(2):206-7. DOI: 10.1093/ptj/67.2.206. View

4.
Sawa G, Paty D . The use of baclofen in treatment of spasticity in multiple sclerosis. Can J Neurol Sci. 1979; 6(3):351-4. DOI: 10.1017/s0317167100023994. View

5.
Dario A, Tomei G . A benefit-risk assessment of baclofen in severe spinal spasticity. Drug Saf. 2004; 27(11):799-818. DOI: 10.2165/00002018-200427110-00004. View